Apr 7, 2001
You indicated on your march 23,2001 answer it is best to wait until approval of Pegasys. Is this superior to the peg-intron that was recently approved? Thank you
| Response from Dr. Rodriguez-Torres
There are differences between the 2 Peg-IFN .Peg-intron is a 12kd compound and Pegasys is a much larger drug of 40kd.The peg moiety is also different in that Peg-intron is a lineal peg and Pegasys is a branched peg.The distribution of the peg in the body also differs in that Pegasys does not goes significantly in extrahepatic tissue and peg-intron does.There are also concerns about the bond between the peg and intron,that may separate easily.The branched peg in Pegasys would be more resistant to the proteolytic enzimes. I think that the pharmacologic data support the conclussion that Pegasys is a superior Peg.This does not means that patients would not respond to Peg-intron.The available data show that Pegasys will be a better choice for genotypes 1 ,renal patients,and non-responders. You need to discuss this with your doctor.Most of the patients can wait 1-2 months to start treatment,and have all the alternatives available.
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.